{"entity":{"id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","aka":["LIGHTBEAM-U01"],"tldr":"A phase 1/2 trial of Patritumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) is a phase 1/2 interventional study registered as NCT06941272 by Merck Sharp & Dohme LLC, with 50 participants planned, started 2025-05-26 and due to reach its primary completion in 2030-12-30. Interventions recorded: Patritumab Deruxtecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06941272","url":"https://clinicaltrials.gov/study/NCT06941272"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["patritumab-deruxtecan"],"companies":["merck","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06941272","phase":"1/2","setting":"LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06941272","source":"https://clinicaltrials.gov/study/NCT06941272","fetchedAt":"2026-10-07T16:55:18.467Z","studySha256":"6937bdd966fd5ad9be2b1a2e1144099dfe06d62624939bb6a4e447aafb3301ae","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"1 Month","maximumAge":"17 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":50,"enrolmentType":"ESTIMATED","siteCount":64,"recruitingSiteCount":64,"countries":["Australia","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-05-26","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06941272/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}